Search Result

Results for "

Mesothelioma

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Anaplastic lymphoma kinase (ALK) (1) Apoptosis (8) Cuproptosis (1) Dipeptidyl Peptidase (1) DNA/RNA Synthesis (1) Endogenous Metabolite (1) ERK (1) FAK (2) Guanylate Cyclase (2) HDAC (2) Microtubule/Tubulin (1) p38 MAPK (1) Phosphatase (1) Reference Standards (1) ROS Kinase (1) Trk Receptor (1) YAP (6)
By Research Areas:	Cancer (20) Cardiovascular Disease (2) Infection (1) Inflammation/Immunology (1) Metabolic Disease (1)
Oligonucleotides:	Phospholipids (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Inhibitory Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-101255

ODQ 4 Publications Verification	Guanylate Cyclase Apoptosis	Cancer
ODQ is a potent and selective soluble guanylyl cyclase (sGC, nitric oxide-activated enzyme) inhibitor. ODQ enhances the pro-apoptotic effects of Cisplatin in human mesothelioma cells .

HY-P99299

Lexatumumab HGS-ETR 2; ETR2-ST01	Apoptosis	Cancer
Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research .

HY-138565

K-975 Maximum Cited Publications 22 Publications Verification	YAP	Cancer
K-975 is a potent, selective and orally active TEAD inhibitor, with a strong inhibitory effect against protein-protein interactions between YAP1/TAZ and TEAD. K-975 covalently binds to Cys359 located in the palmitate-binding pocket of TEAD via an acrylamide structure. K-975 exhibits antitumor activity on malignant pleural mesothelioma .

HY-163644

VT-105	YAP	Cancer
VT-105 is a potent and selective TEAD autopalmitoylation inhibitor that inhibits proliferation and tumor growth in NF2-deficient mesothelioma.

HY-101255R

ODQ (Standard)	Reference Standards Guanylate Cyclase Apoptosis	Cancer
ODQ (Standard) is the analytical standard of ODQ. This product is intended for research and analytical applications. ODQ is a potent and selective soluble guanylyl cyclase (sGC, nitric oxide-activated enzyme) inhibitor. ODQ enhances the pro-apoptotic effects of Cisplatin in human mesothelioma cells .

HY-P991315

Anti-MSLN/Mesothelin (h7D9.v3) RG7600 antibody		Cancer
Anti-MSLN/Mesothelin (h7D9.v3) is a human monoclonal antibody (mAb) targeting MSLN. Anti-MSLN/Mesothelin (h7D9.v3) can be used in ovarian cancer, mesothelioma, and pancreatic cancer research .

HY-P991551

YS110	Dipeptidyl Peptidase p38 MAPK ERK	Infection Cancer
YS110 is a humanized anti-CD26 (DPP4) IgG1 monoclonal antibody. YS110 induces CD26 nuclear translocation through the caveolin pathway. YS110 inhibits the proliferation of tumor cell by delaying G2/M cell cycle transition. YS110 inhibits the infection of Middle East respiratory syndrome coronavirus (MERS CoV) by blocking the binding of MERS CoV S1 to CD26. YS110 can be used for research on cancer or infection such as Malignant Mesothelioma and MERS .

HY-157673

1,2-Dipalmitoleoyl-sn-glycero-3-phosphoethanolamine 16:1 PE	Phosphatase Apoptosis	Cancer
1,2-Dipalmitoleoyl-sn-glycero-3-phosphoethanolamine (16:1 PE) is a phosphatidylethanolamine that can enhance PP2A and PTP1B activities in malignant pleural mesothelioma cells. 1,2-Dipalmitoleoyl-sn-glycero-3-phosphoethanolamine induces apoptosis of NCI-H28 malignant pleural mesothelioma cells .

HY-129976

Pemetrexed tromethamine (dihydrochloric) dihydrate	Endogenous Metabolite	Cancer
Pemetrexed tromethamine dihydrochloric dihydrate is a chemotherapy drug used to treat pleural mesothelioma and non-small cell lung cancer, exhibiting potent anti-cancer activity.

HY-15406

BNC105P	Microtubule/Tubulin	Cardiovascular Disease Cancer
BNC105P is a phosphate prodrug of BNC105 (HY-16114), that exhibits activity as a vascular disrupting agent (VDA) and an antitumor agent through conversion to active BNC105 .

HY-147135

MYF-03-69 TEAD-IN-3	YAP	Cancer
MYF-03-69 (TEAD-IN-3) is a potent and irreversible TEAD inhibitor. MYF-03-69 disrupts YAP-TEAD association, suppresses TEAD transcriptional activity and inhibits cell growth of Hippo signaling defective malignant pleural mesothelioma (MPM) .

HY-153811

IAG933 YAP-TEAD-IN-3	YAP Apoptosis	Cancer
IAG933 (YAP-TEAD-IN-3) is an orally available YAP/TAZ-TEAD inhibitor that has anti-tumor effects and promotes apoptosis. IAG933 YAP-TEAD-IN-3 inhibits Avi-human TEAD ^4217-434, with an IC₅₀ value of 9 nM .

HY-128530

Tetrathiomolybdate	Cuproptosis	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Tetrathiomolybdate, an orally active anti-copper agent, reduces copper levels in the body. Tetrathiomolybdate has a protective effect on collagen-induced arthritis in mice. Tetrathiomolybdate also reduces blood sugar, but has no effect on mice with hereditary diabetes (db/db). Tetrathiomolybdate inhibit angiogenesis, also shows antiangiogenic effects in malignant pleural mesothelioma .

HY-143411

GEM144	HDAC Apoptosis DNA/RNA Synthesis	Cancer
GEM144 is a potent and orally active DNA polymerase α (POLA1) and HDAC 11 dual inhibitor. GEM144 induces acetylation of p53, activation of p21, G1/S cell cycle arrest, and apoptosis. GEM144 has significant antitumor activity in human orthotopic malignant pleural mesothelioma xenografts .

HY-122844B

Ifebemtinib tosylate BI-853520 tosylate; IN-10018 tosylate	FAK	Cancer
Ifebemtinib (tosylate) (BI-853520 (tosylate); IN-10018 (tosylate)) is a highly selective PTK2 kinase inhibitor. Ifebemtinib (tosylate) demonstrates anti-tumor activity. Ifebemtinib (tosylate) inhibits FAK autophosphorylation in prostate carcinoma cells. Ifebemtinib (tosylate) can inhibit spheroid formation and orthotopic tumor growth in vivo. Ifebemtinib (tosylate) can be studied in anticancer research such as solid tumors, breast cancer, and malignant pleural mesothelioma .

HY-147136

MYF-03-176	YAP	Cancer
MYF-03-176 is an orally active inhibitor of TEAD, and suppresses TEAD transcriptional activity with an IC₅₀ of 11 nM. The IC₅₀ values of MYF-03-176 for TEAD1, TEAD3, and TEAD4 are 47, 32, and 71 nM, respectively. MYF-03-176 inhibits hippo signaling defective malignant pleural mesothelioma (MPM) cells. MYF-03-176 shows strong antitumor efficacy in MPM mouse xenograft model .

HY-134957

VT107 5+ Cited Publications	YAP	Cancer
VT-107, as an analogous to VT104, is an orally active and potent pan-TEAD auto-palmitoylation inhibitor. VT-107 can be used for the research of cancer .

HY-155163

APG-2449	Anaplastic lymphoma kinase (ALK) ROS Kinase FAK Apoptosis	Cancer
APG-2449 is an orally active inhibitor for BCL-2 and multikinase (ALK/FAK/ROS1) with potent antitumor activities. APG-2449 reduces cell viability and enhances apoptosis in acute myeloid leukemia cells in vitro. APG-2449 decreases activation of FAK and its downstream effectors. APG-2449 can be studied in research for mesothelioma tumor, non-small cell lung cancer, ovarian cancer, hematologic and solid malignancies .

HY-171450

VMD-928	Trk Receptor	Cancer
VMD-928 is an orally active, allosteric, irreversible and selective tropomyosin receptor kinase A (TrkA) inhibitor. VMD-928 blocks the downstream signaling pathways triggered by the binding of nerve growth factor (NGF) to TrkA, thereby inhibiting cell proliferation, invasion, and promoting cancer cell death. VMD-928 is promising for research of various cancers, including prostate cancer, thymic carcinoma, mesothelioma, squamous cell carcinoma of the head and neck, squamous cell carcinoma of the lung, ovarian cancer, hepatocellular carcinoma .

HY-W009776

Suberoyl bis-hydroxamic acid Suberohydroxamic acid; SBHA	HDAC Apoptosis	Cancer
Suberoyl bis-hydroxamic acid (Suberohydroxamic acid; SBHA) is a competitive and cell-permeable HDAC1 and HDAC3 inhibitor with ID₅₀ values of 0.25 μM and 0.30 μM, respectively .Suberoyl bis-hydroxamic acid renders MM cells susceptible to apoptosis and facilitates the mitochondrial apoptotic pathways .Suberoyl bis-hydroxamic acid can be used for the study of medullary thyroid carcinoma (MTC) .

Cat. No.	Product Name	Type

HY-157673

1,2-Dipalmitoleoyl-sn-glycero-3-phosphoethanolamine 16:1 PE	Drug Delivery
1,2-Dipalmitoleoyl-sn-glycero-3-phosphoethanolamine (16:1 PE) is a phosphatidylethanolamine that can enhance PP2A and PTP1B activities in malignant pleural mesothelioma cells. 1,2-Dipalmitoleoyl-sn-glycero-3-phosphoethanolamine induces apoptosis of NCI-H28 malignant pleural mesothelioma cells .

Cat. No.	Product Name	Target	Research Area

HY-P99299

Lexatumumab HGS-ETR 2; ETR2-ST01	Apoptosis	Cancer
Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research .

HY-P991315

Anti-MSLN/Mesothelin (h7D9.v3) RG7600 antibody		Cancer
Anti-MSLN/Mesothelin (h7D9.v3) is a human monoclonal antibody (mAb) targeting MSLN. Anti-MSLN/Mesothelin (h7D9.v3) can be used in ovarian cancer, mesothelioma, and pancreatic cancer research .

HY-P991551

YS110	Dipeptidyl Peptidase p38 MAPK ERK	Infection Cancer
YS110 is a humanized anti-CD26 (DPP4) IgG1 monoclonal antibody. YS110 induces CD26 nuclear translocation through the caveolin pathway. YS110 inhibits the proliferation of tumor cell by delaying G2/M cell cycle transition. YS110 inhibits the infection of Middle East respiratory syndrome coronavirus (MERS CoV) by blocking the binding of MERS CoV S1 to CD26. YS110 can be used for research on cancer or infection such as Malignant Mesothelioma and MERS .

Cat. No.	Product Name		Classification

HY-157673

1,2-Dipalmitoleoyl-sn-glycero-3-phosphoethanolamine 16:1 PE		Phospholipids
1,2-Dipalmitoleoyl-sn-glycero-3-phosphoethanolamine (16:1 PE) is a phosphatidylethanolamine that can enhance PP2A and PTP1B activities in malignant pleural mesothelioma cells. 1,2-Dipalmitoleoyl-sn-glycero-3-phosphoethanolamine induces apoptosis of NCI-H28 malignant pleural mesothelioma cells .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.